Century Therapeutics 2025 net loss narrows beating estimates

Century Therapeutics

12/03/2026 12:10

Overview

US biotechnology firm's 2025 net loss narrowed, beating analyst expectations

Collaboration revenue for 2025 surged, driven by Bristol-Myers Squibb agreement

Company completed $135 mln private placement, extending cash runway into Q1 2029

Outlook

Century expects to submit CNTY-813 IND in 4Q 2026, with initial clinical data in 2H 2027

Company expects CNTY-308 to enter the clinic in 2026, pending regulatory clearance

Century anticipates updated preliminary clinical data from the CARAMEL study in 2026

Result Drivers

COLLABORATION REVENUE - Surge in collaboration revenue attributed to Bristol-Myers Squibb agreement

LOWER R&D AND G&A COSTS - Decline in research and development and administrative expenses due to reduced personnel, manufacturing, and legal costs

Company press release: ID:nGNX7Qd8DN

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Collaboration Revenue
$109.16 mln
FY Net Income
Beat
-$9.58 mln
-$14.72 mln (3 Analysts)
FY Operating Income
Beat
-$17.27 mln
-$20.86 mln (3 Analysts)
FY Basic EPS
-$0.14
FY Operating Expenses
$126.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Century Therapeutics Inc is $4.00, about 46.5% above its March 11 closing price of $2.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)